Tag Archives: Chronic

FDA Approves Kerendia (finerenone) for the Treatment of Patients with Chronic Kidney Disease Associated with Type 2 Diabetes

FDA Approves Kerendia (finerenone) for the Treatment of Patients with Chronic Kidney Disease Associated with Type 2 Diabetes WHIPPANY, N.J.– July 9, 2021 (BUSINESS WIRE)– Bayer announced today the United States (U.S.) Food and Drug Administration (FDA) has approved Kerendia (finerenone), a first-in-class nonsteroidal mineralocorticoid receptor antagonist (MRA) indicated to reduce the risk of sustained… Read More »

How I Healed My Chronic Gut Issues & Weight Fluctuations

From my late teens to the early ’20s, I suffered from chronic gut issues, leading to easy and unexplained weight fluctuations, low energy, and an immense amount of pain and frustration every single day – things weren’t adding up for me. I was a healthy woman and was always so focussed on my health, doing… Read More »

What is chronic pancreatitis diet

Enzyme Supplementation If pancreatic enzymes are prescribed, it is important to take them regularly in order to prevent flare-ups. Chahal says. The same enzymes that help with digestion can sometimes injure the pancreas and cause irritation. The less you consume, the less burden you put on your pancreas which, due to pancreatitis, is already challenged… Read More »

Chronic pain: Antidepressants not painkillers recommended

Doctors are being advised not to prescribe common painkillers, including paracetamol and ibuprofen, for patients with chronic pain not caused by an injury or other medical condition. The National Institute of Health and Care Excellence (NICE) said there was little evidence they help. And it suggests there is evidence long-term use can be harmful. Its… Read More »

FDA Approves Epclusa (sofosbuvir/velpatasvir) for Children Ages 6 and Older or Weighing at Least 17 kg with Chronic Hepatitis C Infection

Print this page FOSTER CITY, Calif.–(BUSINESS WIRE)– Gilead Sciences, Inc. (NASDAQ: GILD) announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Epclusa® (sofosbuvir 400mg/velpatasvir 100mg; sofosbuvir 200mg/velpatasvir 50 mg) for the treatment of people with chronic hepatitis C infection (HCV) as young as 6 years of age or weighing at… Read More »

FDA Approves Ofev (Nintedanib), For The Treatment of Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype

FDA Approves Ofev (Nintedanib), For The Treatment of Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype Print this page March 09, 2020 — The U.S. Food and Drug Administration today approved Ofev (nintedanib) oral capsules to treat patients with chronic fibrosing (scarring) interstitial lung diseases (ILD) with a progressive phenotype (trait). It is the… Read More »